Titre :

Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies? a review from the chronic malignancies working party of the ebmt

Auteur(s) :

Garderet, Laurent [Auteur]
Morris, C. [Auteur]
Beksac, Meral [Auteur]
Gahrton, G. [Auteur]
Schonland, Stefan O. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Hayden, Patrick J. [Auteur]

Titre de la revue :

Biology of blood and marrow transplantation . journal of the American Society for Blood and Marrow Transplantation

Nom court de la revue :

Biol. Blood Marrow Transplant.

Date de publication :

2020-05-14

ISSN :

1523-6536

Mot(s)-clé(s) :

Immunotherapy
Myeloma
Autologous stem cell transplantation
CAR T cells

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Melphalan at a myeloablative dose followed by autologous stem cell transplantation (ASCT) remains the standard of care for transplant-eligible patients with myeloma. However, therapies such as new immunomodulatory drugs ...
Lire la suite >Melphalan at a myeloablative dose followed by autologous stem cell transplantation (ASCT) remains the standard of care for transplant-eligible patients with myeloma. However, therapies such as new immunomodulatory drugs and proteasome inhibitors and, more recently, monoclonal antibodies and chimeric antigen receptor T cells are challenging the traditional role of ASCT. Which patients benefit from ASCT? Can its use be delayed until first relapse? The field is moving rapidly as novel agents lead to new patient care strategies. The place of ASCT in this changing landscape will be reviewed and reassessed.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:48:04Z